ERA has the knowledge and experience to assist at all stages of product development, from conception to registration, and beyond.
Our expertise covers a wide range of products (around 400 products to date), incorporating recombinant DNA and hybridoma technology, synthetic peptides, conventional and advanced vaccines, classical blood products, advanced therapy medicinal products comprising gene therapy, somatic cell therapy and tissue-engineered products.
We also consult on innovative new chemical entities, particularly those indicated for neurological, oncological and immunological diseases. Last, but not least, the ERA team includes specialists for companion diagnostics and biomarkers, offering dedicated services in this cutting edge field.
Our team of more than 30 professionals includes scientists with a research and development background, those with extensive industry experience and former regulators, offering both breadth and depth of expertise, from which our clients can benefit. ERA has office facilities in Germany, the UK, the USA and Australia, with the in-house capability to prepare documents and complete submissions on behalf of clients, including a dedicated eCTD group.